Neoantigen-based Personalized, Immune Cell Therapy for Patients with Advanced NSCLC: A Pilot Study.

Zhenyu Ding,Li Yang,Han-Suo Yang,Heng Xu

DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.e15043

IF: 45.3

2018-01-01

Journal of Clinical Oncology

Abstract:e15043 Background: Immune cell therapy remains a promising strategy for cancer therapy, however the lack of specificity restrains its application. Here a personalized, neoantigen-based dendritic cell (DC) therapy protocol was evaluated in this pilot study. Methods: Advanced NSCLC patients without standard of care with measurable tumor were enrolled. Whole exon sequencing was performed in DNA from the freshly obtained tumor tissues as well as the peripheral blood, while RNA-seq was performed in tumor-derived RNA. Somatic mutations were submitted to systematical program of neoantigen prediction, considering personalized MHC affinity, gene expression, tumor heterogeneity, and etc. Finally, 10-15 peptides with the highest score were synthesized and pulsed into PBMC-derived DC. DC was then introduced into patients together with cytokine-induced killer cells. All cells were prepared in a GMP workshop. The primary endpoint was safety and tolerability. Results: Totally six patients were enrolled up to now. All were adenocarcinoma with no known sensitive mutation. They were heavily treated (lines of previous therapy: 2, 5, 2, 2). Four out of these six patients (3 males and 1 female) finally received cell transfer, with one patient died rapidly before preparation of neoantigen-based cells, and the other one lacked candidate neoantigens. Patients 1 had 90% expression of PD-L1 on tumor cells while the other 3 patients were negative, while Patient 2 had been treated with nivolumab before enrollment. 35, 305, 51, and 68 candidate neoantigens were identified from each patient, respectively, and the top 10-15/patients were synthesized for DC cell stimulation. Totally 37 times of cell infusion was administered (8, 7, 17, and 5 for each). The cell infusion was safe and highly tolerable and no significant side effects were observed, even for those with poor performance. The treatment achieved SD in 3 patients, but it lasted for only 1-1.5 m in patient 1&2. Patient 3 remained well for 6 m and progressed. Patient 4 is now maintained on therapy. Conclusions: The neoantigen-based personalized immune cell therapy was highly tolerable without obvious side effects. Optimizations are required to improve anti-tumor efficacy. Clinical trial information: NCT02956551.